PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne

May 19, 2023

Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001

May 24, 2023

Antisense Receives Approval to Conduct Phase IIb Trial of ATL1102 and Appoints New CEO

May 23, 2023

On May 23, 2023, Antisense Therapeutics announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy in Bulgaria. They also announced the appointment of their new CEO, Dr. James Garner, MBBS, MBA.

To read their ATL1102 trial press release, please click here.

To read their press release announcing the appointment of their CEO, please click here.

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

© 2024 All rights reserved. Powered by Getfused

Support Jett Foundation

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)